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Stomach cancer ranks second to lung cancer in the global cancer burden. It is estimated that 25% of families meeting the
criteria for hereditary diffuse gastric carcinoma (HDCG) will have germline mutations in the E-cadherin gene. Evidence
suggests that stomach cancer might also be a malignant manifestation of other inherited predispositions to disease. Recently, it
has been reported that the incidence of stomach cancer is signiﬁcantly increased in BRCA2 gene mutation carriers. We
analysed by direct sequencing the BRCA2 gene in 29 breast cancer patients derived from 29 families with an aggregation of at
least one female breast cancer diagnosed before the age of 50 years and one male stomach cancer diagnosed before the age
of 55 years. In all but one of these families at least one additional relative was also affected by a malignant tumour. We
identiﬁed three frameshift mutations and three sequence variants – potentially missense mutations, in six unrelated patients
representing 20.7% (six out of 29) of the families investigated. Our results conﬁrm that BRCA2 gene mutations are also
associated with familial aggregations of not only breast but also of stomach cancer. In comparison to the number of cancers
expected in the study population compared to the general population there is an over-representation of several cancers with
signiﬁcant conﬁdence intervals to suggest that the associations are real and not a selection artefact.
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Stomach cancer is the second most common epithelial cancer, and
thereby represents a signiﬁcant global cancer burden (La Vecchia et
al, 1992). The ﬁrst description of a genetic predisposition to famil-
ial stomach cancer came from the identiﬁcation of germline
mutations of the E-cadherin gene in Maori kindreds from New
Zealand, where patients presented with an early onset, diffuse type
cancer (Becker et al, 1994; Guilford et al, 1998). It has been esti-
mated that only 25% of families meeting the criteria for
hereditary diffuse gastric carcinoma (HDCG) will have germline
mutations in the E-cadherin gene (Caldas et al, 1999). Stomach
cancer has also been shown to be part of the tumour spectrum
in other inherited syndromes, including hereditary non-polyposis
colon cancer, otherwise known as HNPCC (Scott et al, 2001a),
familial adenomatous polyposis (FAP) (Scott et al, 2001b),
Peutz–Jeghers syndrome (Hizawa et al, 1993), Cowden’s syndrome
(Hamby et al, 1995) and the Li–Fraumeni syndrome (Scott et al,
1993).
Recently it has been shown that not only breast and ovarian but
also other cancers are over-represented in BRCA2 linked families
(BCLC, 1999; Johannsson et al, 1999). It has also been shown that
the frequency of the BRCA2 6174delT mutation among consecutive
Jewish patients with stomach cancer is 5.7%, which is approxi-
mately ﬁve times higher than in the general population (Figer et
al, 2001). There is also evidence to suggest that the increased
frequency of stomach cancers in BRCA2 carriers may be sex
related, as it occurs primarily in males (BCLC, 1999; Johannsson
et al, 1999).
In Polish families, with a strong aggregation of breast and ovar-
ian cancers and no other cancer, the frequency of BRCA2
mutations is very low and does not exceed 5–10% (van Der Looij
et al, 2000; Grzybowska et al, 2000; Go ￿rski unpublished data).
Given the high frequency of breast and stomach cancer families
observed in our familial breast cancer data base, we analysed the
BRCA2 gene by direct DNA sequencing to determine the frequency
and nature of BRCA2 germline mutations in families where there
was a clear aggregation of breast and male stomach cancers occur-
ring at early ages.
MATERIALS AND METHODS
Twenty-nine families with an aggregation of at least one female
breast cancer diagnosed before the age of 50 years and one male
stomach cancer diagnosed under the age of 55 years were available
for study. In 28 of these families at least one additional relative was
diagnosed with a malignant tumour (Table 1). In 12 families
stomach cancer was diagnosed in a ﬁrst-degree relative of an early
onset breast cancer proband (families 1–12). In 17 breast cancer
families, stomach cancer was diagnosed among second degree rela-
tives through an unaffected woman (10 cases, families 13–22) or
through an unaffected male (seven cases, families 23–29). A
control population of 100 healthy unaffected unrelated individuals
was used for the assessment of potential pathogenic missense
changes. For a comparison of the clinical features and age of diag-
nosis of malignancies of the 29 families see Table 1.
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patients affected by breast cancer and from the 100 healthy
controls (Lahiri and Schnabel, 1993).
None of the cancer patients showed signs of the ﬁve common
Polish founder BRCA1 mutations (Go ￿rski et al, 2000). The entire
coding sequence of the BRCA2 gene was ampliﬁed in 27 separate
PCR reactions, using primers and conditions described previously
(BCLC, http://www.nhgri.nih.gov/Intramural_research/Lab_trans-
fer/Bic/Member/BRCA2.html), with minor modiﬁcation. Instead
of subdividing exons 11, 10, 14 and 27 due to their size, each were
ampliﬁed in one fragment, using primers located in the adjacent
introns. After puriﬁcation, all PCR products were analysed on an
ABI 377 DNA Sequencer with the primers described previously
(BCLC,http://www.nhgri.nih.gov/Intramural_research/Lab_transfer/
Bic/Member/BRCA2.html).
Standard incidence rates (SIRs) and conﬁdence intervals (CIs) for
the various cancer sites were calculated by the conventional method,
which assumes all events are independent, and by a method which
adjusts for intrafamilial correlation. The unadjusted method uses
the formulae: SIR=O/E, SE(log SIR)=1/O
1/2, so that a 95% CI for
the estimated SIR is given by O/E6exp(+1.9661/O
1/2), where O
is the observed number of cases and E is the expected number of
cases according to the standard population rates. In our case, the
standard rates are the Polish cancer incidence rates. The expected
number of cases in each family is the standard rate times the number
of family members. Expected number of cases for female-only
cancers were calculated using the corresponding number of female
family members.
The same results are obtained by ﬁtting a Poisson model with
only a constant term to the observed number of cases, using the
corresponding expected number of cases in each family as the total
exposure (or denominator of rate) for each family (see Clayton and
Hills, 1993). This suggests an approach for adjusting for intrafami-
lial correlation, which is to ﬁt the same model but to calculate
robust standard errors that allow for this extra source of variation.
The results for the adjusted approach are affected mainly via their
standard errors, but if the number of observed cases is small, the
SIR estimate will also be affected. All other statistical tests were
performed using the STATA statistical package.
RESULTS
From the 29 families, three frameshifts and three variants, potentially
missense mutations, in six unrelated probands representing – 20.7%
of families were identiﬁed. Two of the detected frameshift mutations
(886delGT, 6696delTC) have been previously reported in BIC
(http://www.nhgri.nih.gov/Intramural_research/Lab_transfer/Bic/
index.html). One mutation (9174delA) localised in exon 22 and the
three potential missense changes represented novel variations in the
BRCA2 gene (Table 1). None of these changes were present in the
100normalhealthycontrolsamples,consistentwiththepossibilitythat
they are missense changes and are more than just rare polymorphisms.
In three families the association of detected abnormalities in the
BRCA2 gene with stomach cancer was supported by analyses of the
occurrence of these changes in relatives. In families No 3 and 23
mutations were detected in probands with breast cancer but not
in the maternal side of family where stomach cancer was not
observed (Figure 1A,B). In family No 11 the mutation was present
in the proband and an obligatory carrier – the sister of proband
being the mother of a stomach cancer patient (Figure 1C). DNA
from relatives of the probands from families 14, 21 and 25 with
BRCA2 gene alterations was unavailable for analysis.
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Table 1 Occurrence of malignant tumours and detected germline alterations in tested families
No of No of Detected alteration in
breast cancers stomach cancers DNA and consequence
Family (age at diagnosis) (age at diagnosis) Other cancers at protein level
1 4 (41–46) 1 (44) –
2 3 (45, 48) 1 (36) lar, lung
3 3 (35–45) 1 (49) – 886delGT, V220fs223X
4 3 (40–50) 1 (49) 26kid, leu
5 3 (30–48) 1 (54) Leu
6 2 (42) 1 (50) –
7 2 (48, 71) 2 (38, 35) –
8 2 (47, 56) 2 (40, 64) pan, lung, 26leu
9 1 (39) 2 (44, 30) –
10 1 (39) 1 (50) Liv
11 1 (49) 2 (27, 30) Panc 6509A/G, Y2094C*
12 1 (42) 4 (48–60) –
13 3 (44–64) 1 (27) –
14 2 (35, 36) 1 (54) – 9174delA, K2982fs2987X*
15 2 (42, 52) 1 (45) FGT
16 2 (30, 76) 1 (50) –
17 1 (49) 2 (42, 44) col, lar
18 1 (47) 2 (48, 61) panc, lar
19 1 (43) 2 (52, 68) –
20 1 (39) 2 (22, 52) –
21 1 (25) 1 (52) – 6696delTC, S2156fs2174X
22 1 (41) 1 (50) Leu
23 3 (46–67) 1 (52) Lung 6612A/C, K2128N*
24 2 (47, 50) 1 (42) Brain
25 2 (46, 64) 1 (45) lar 6443C/G, S2072C*
26 1 (36) 1 (52) lung
27 1 (41) 1 (55) bl
28 1 (45) 1 (51) col, CSU
29 1 (45) 1 (54) kid, panc
Col, colon; panc, pancreas; lar, larynx; bl, urinary bladder; kid, kidney; leu, leukaemia; liv, liver; CSU, cancer site unknown;
FGT, female genital tact. *Alteration reported for the ﬁrst time
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was among 18 relatives, BRCA2 abnormalities were detected in two
out of 12 cases (one frameshift, one assumed missense variation;
16.7%). In families with stomach cancers among 28 relatives,
BRCA2 changes were identiﬁed in four out of 17 cases (two frame-
shifts, two assumed missense variations; 23.5%).
To further verify the uniqueness of the population under inves-
tigation, a statistical comparison was performed to determine if the
observed cancers in the families were due to chance or most prob-
ably a result of a genetic predisposition. The relative frequency of
the reported malignancies, compared to those of the general popu-
lation, revealed several signiﬁcant differences as shown in Table 2.
As expected in the study population breast and stomach cancers
are over-represented with a high degree of conﬁdence. Interest-
ingly, leukaemia is also signiﬁcantly over-represented followed by
pancreatic cancer. All other cancers shown in Table 2 (except brain
and bladder) are over-represented, but the conﬁdence intervals
were such that the signiﬁcance was not as striking by virtue of
the fact that the actual numbers of cancers within the study popu-
lation were low.
When the families are sub-divided into those that harbour
mutations in BRCA2 and compared to those that do not, further
differences and similarities were observed. When compared against
each other the overall frequency of cancers in the mutation nega-
tive group was signiﬁcantly different (P50.001) to that of the
mutation positive group (25.3 and 17.5%, respectively). The
frequency of breast cancer within the mutation negative group
accounted for the difference in cancer incidence between the two
groups. The frequency of stomach cancer was identical in both
groups (7%). There were too few other cancers to determine if
there were differences between the two groups.
Finally, a comparison was made between the frequency of
BRCA2 mutations in this study population compared to the
frequency of BRCA2 mutations in breast ovarian cancer families.
Collectively 248 breast/ovarian cancer families have thus far been
screened for BRCA2 mutations, and 17 have been identiﬁed (van
der Looij et al, 2000, Grzybowska et al, 2000 and Go ￿rski unpub-
lished data). Using Fishers exact test we observed a signiﬁcant
difference between the incidence of BRCA2 mutations in the
breast/male stomach cancer families compared to the breast/ovar-
ian cancer families (P50.025).
DISCUSSION
Currently there is little information about the nature and frequency
of BRCA2 constitutional mutations in families selected for the
coexistence of breast and stomach cancers. In an earlier study it
was reported that male stomach cancer was over-represented in
BRCA2 mutation positive families. Veriﬁcation of this relationship
between breast and stomach cancer in our series of cases suggests
that this disease constellation can be used as a phenotypic indicator
for the pre-selection of families for BRCA2 testing. Unfortunately,
the stomach cancer patients had succumbed to their disease and it
was impossible to obtain mutation data from any of them.
Notwithstanding, the stomach cancer cases were on the same trans-
mitting lineage of the mutation, were diagnosed with disease under
the age of 55 and it remains highly likely that they were gene
carriers.
The SIRs for breast and stomach cancer in the families presented
in this report is highly signiﬁcant, indicating that it is a real entity
and not a chance association, and it provides additional evidence
that male stomach cancer is part of the spectrum of disease in
BRCA2 families. Similarly, other cancers are over-represented
providing additional evidence that BRCA2 mutations result in a
less restricted disease phenotype than BRCA1 mutations. A signiﬁ-
cant difference in cancer incidence was observed between the two
groups, which could be accounted for by the increased frequency
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
s
(–)
(–)
br 44
(+)
br 35
br 45 st 49
br 50
lu 64 br 67 st 67
br 46
(+)
br 49
(+)
st 27 (+)
st 30
A
B
C
Figure 1 Pedigrees of three families carrying the BRCA2 alterations: 3
(A), 23 (B) and 11 (C). st, stomach cancer; br, breast cancer; lu, lung cancer;
pan, pancreatic cancer; numbers in brackets indicate age at diagnosis of can-
cer; (+), (7) indicate presence or absence of BRCA2 alteration.
Table 2 Standard incidence rates of the cancers identiﬁed in the 29
families
Unadjusted Adjusted
Site SIR 95% CI SIR 95% CI
Breast
a 576.8 439.5, 756.9 576.8 473.7, 702.2
Breast
b 584.1 445.1, 766.5 584.1 479.9, 710.8
Stomach 597.7 429.1, 832.5 597.7 449.7, 794.4
Laryngeal 134.7 50.5, 358.8 160.1 44.9, 571.5
Kidney 84.8 27.4, 263.0 94.8 24.2, 371.8
Leukaemia
c 260.3 108.3, 625.4 256.2 98.4, 666.9
Pancreas 137.1 51.4, 365.2 137.1 52.6, 357.5
Colon 40.4 10.1, 161.6 40.4 10.3, 158.7
Brain 35.8 5.0, 254.2 20.2 2.9, 140.8
Liver 60.1 8.5, 426.6 183.4 25.7, 1311.1
Lung 29.2 13.1, 65.1 29.2 13.7, 62.2
Bladder 27.2 3.8, 193.2 28.2 3.9, 202.3
FGT 212.2 29.9, 1506.6 212.2 29.9, 1504.2
aExpected count includes both males and females.
bExpected count includes females
only.
cExpected number of cases based on lymphatic and myeloid leukaemia rates.
Unadjusted SIRs do not take into account the relation between groups of patients
whereas the adjusted SIRs do. The overall difference in rates is not changed, but the
conﬁdence intervals are altered indicating that the statistical signiﬁcance of the results
is affected by familial relationships. Overall, all but two cancer types (brain and
bladder) are signiﬁcantly over-represented
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is most likely due to fragmentary pedigree information (due to the
decimation of this population in recent history) and is unlikely to
represent an actual difference between the two groups.
Three mutations in this study can be clearly identiﬁed as causa-
tive, whilst the remaining three represent missense changes which
can not unequivocally be assigned as causative. The missense
changes occurred in a small region of the BRCA2 gene (from posi-
tion 6443 to 6612) within 169 base pairs of one another and were
all identiﬁed in patients with breast cancer and not in 100 control
subjects. The amino acid changes conferred by the missense
changes were not conservative, one change was a tyrosine to
cysteine, the second a serine to cysteine and the third a lysine to
asparagine. The introduction of a cysteine is likely to interact with
other cysteines, which occur within this region of the gene and
thereby disrupt the structural and functional activity of the protein.
Since we do not know of any functional domains in this region of
the gene it is impossible to determine the functional signiﬁcance of
these changes. Nevertheless, the evidence suggests that these
missense mutations are likely to affect the function of the protein.
It has been shown that BRCA2 mutations are characterised by a
lower level of penetrance than in BRCA1 mutation carriers (Boyd,
1996; Levy-Lahad et al, 1997). The results presented here support
these ﬁndings, since we detected BRCA2 changes almost twice as
frequently in patients without cancers among ﬁrst degree relatives
compared to patients with cancers diagnosed in parents or siblings
(Boyd, 1996; Roa et al, 1996; Levy-Lahad et al, 1997; Risch et al,
2001).
The frequency of BRCA2 mutations identiﬁed in this population
compared to similar studies targeting breast/ovarian cancer families
indicates that the stomach/breast constellation may be a more
speciﬁc phenotypic marker for BRCA2 mutations, and as such,
be of beneﬁt in assigning patients for BRCA2 mutation screening.
Our results conﬁrm and extend the notion that BRCA2 is likely
to be the molecular basis of at least a subset of stomach cancer
patients. The breast – stomach phenotype is one of several types
of familial tumour aggregation at varying sites associated with
BRCA2 gene mutations. BRCA2 changes have also been related
to other aggregations of malignancy, which include predispositions
to ovarian, pancreatic or skin tumours (BCLC, 1999).
Further investigations are needed in order to describe the actual
involvement of BRCA2 mutations in different types of familial
aggregation of cancers and to assess whether or not there are histo-
pathological differences in stomach cancers that are associated with
mutations in this gene.
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